Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss
Authors:
- 21 May 2018
- journal article
- research article
- Published by Taylor & Francis in Neurological Research
- Vol. 40 (9) , 736-743
Abstract
Objectives: Parkinson’s disease (PD) is a neurodegenerative disease with high morbidity among adults worldwide that causes tremendous trouble to people’s lives. The purpose of this study was to investigate the impact of sitagliptin on PD and its potential mechanism. Methods: First, the memory of rats in each group was evaluated with the Morris water maze (MWM) test and the passive avoidance test. Then, both brain-derived neurotrophic factor (BDNF) protein and mRNA levels were detected by ELISA and qPCR assays, respectively. Then, rapid Golgi impregnation was used to observe the density of dendritic spines in the hippocampal CA1 area. Finally, k252a, an antagonist of Trk receptors, was used to block the binding of BDNF with its receptors, and the effects of sitagliptin on PD improvement were detected. Results: Our study showed that sitagliptin improved memory deficits in PD rats. Meanwhile, the expression level of BDNF and tyrosine hydroxylase (TH) was upregulated, and the density of dendritic spine was increased by sitagliptin administration. Moreover, K252a administration blocked the positive effects of sitagliptin on memory in PD rats. Discussion: Sitagliptin rescued the memory deficits, which was achieved by upregulating BDNF to prevent neuronal death and dendritic spine loss. Our findings indicate that sitagliptin might be a promising potential drug for PD treatment in the future.Keywords
Funding Information
- Harbin University of Science and Technology (2016RAQXJ201)
- Postdoctoral Fund in Heilongjiang Province (LBH-Z15150)
This publication has 39 references indexed in Scilit:
- Sitagliptin enhances the neuroprotective effect of pregabalin against pentylenetetrazole-induced acute epileptogenesis in mice: Implication of oxidative, inflammatory, apoptotic and autophagy pathwaysNeurochemistry International, 2018
- Glitazone use associated with reduced risk of Parkinson's diseaseMovement Disorders, 2017
- BDNF polymorphism associates with decline in set shifting in Parkinson's diseaseNeurobiology of Aging, 2015
- Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's diseaseJournal of the Neurological Sciences, 2015
- Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's diseaseNeurobiology of Disease, 2014
- BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's diseaseNeuroscience Letters, 2014
- Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes MellitusDrugs, 2014
- Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal miceBrain Research, 2013
- Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron culturesNeurobiology of Disease, 2012
- Progression of motor symptoms in Parkinson’s diseaseNeuroscience Bulletin, 2012